Previous studies have shown that simvastatin, a hydroxymethyl glutaryl coenzyme A reductase inhibitor, reduces plasma cholesterol levels when administered once a day. In the present study, the efficacy and tolerability of a morning and an evening dose were compared. The dosages employed were 2.5 and 5 mg for 12 weeks. This investigation was a double-blind, placebocontrolled study involving 172 hyperlipidemic subjects whose plasma cholesterol levels were higher than 220 mg/dl. During the study period, mean changes in plasma cholesterol level (from baseline) were -11% with the 2.5-mg q.a.m. regimen, -15% with the 2.5-mg q.p.m. regimen, -14% with the 5-mg q.a.m. regimen, and -21% with the 5-mg q.p.m. regimen. Each of these changes was statistically significant when compared with that in the placebo group (/><0.001). In addition, the reduction in cholesterol level was significantly greater with the evening regimen than with the morning regimen for both the 2.5-mg (p<0.05) and the 5-mg (p<0.05) dosages. The changes in triglyceride and high density lipoprotein cholesterol levels in each group were not significantly different from those in the placebo group. There were no differences in the incidence of clinical adverse reactions among the various treatment groups. In conclusion, when simvastatin was administered orally once per day in the evening, it reduced cholesterol levels to a significantly greater degree than when it was given in the morning. (Arteriosclerosis and Thrombosis 1991;ll:816-826)
S
erum lipid levels are an important risk factor in atherosclerosis, and successful treatment of hyperlipidemia and especially hypercholesterolemia can reduce the incidence of coronary heart disease. 1 -2 Therefore, it is now argued that it is necessary to reduce elevated serum cholesterol levels.
Cholesterol in the blood originates in large part from its biosynthesis in the liver. Accordingly, it has been suggested that inhibition of hydroxymethyl glutaryl coenzyme A (HMG: CoA) reductase, the ratelimiting enzyme of cholesterol biosynthesis, will lower the serum cholesterol level by inhibiting cholesterol biosynthesis. Recently, it has been reported that reductions in serum cholesterol level can also be caused by the induction of activity of low density lipoprotein (LDL) receptors in the liver. 34 Lovastatin 5 (Merck Sharp & Dohme, West Point, Pa.) and pravastatin 6 (Sankyo K.K., Tokyo, Japan), as inhibitors of HMG: CoA reductase, have already been approved in some countries for use in reducing plasma cholesterol levels.
Simvastatin is an HMG: CoA reductase inhibitor, 7 and it has been demonstrated to produce a marked lowering of serum cholesterol levels in animal (canine) experiments. 8 Since 1985, clinical studies involving patients have been performed in the United States and Europe, and the results have demonstrated that simvastatin is an effective and well-tolerated agent for the treatment of hypercholesterolemia.
In the dosage range of 10-40 mg once a day, simvastatin reduced total cholesterol and LDL cholesterol levels by 22% to 32% and by 28% to 41%, respectively. 910 Since 1986, clinical studies in Japan have also been performed with doses of 2.5-10 mg. vastatin as a single daily dose to reduce plasma cholesterol levels, a double-blind study was performed to compare the results of morning and evening administration of 2.5 and 5 mg simvastatin.
Methods
One hundred seventy-two hyperlipidemic subjects were given placebo or simvastatin at doses of 2.5 mg once daily in the morning, 2.5 mg once daily in the evening, 5 mg once daily in the morning, or 5 mg once daily in the evening under double-blind conditions.
Subjects
The subjects of this clinical study were patients diagnosed as having hyperlipidemia (including patients with familial hypercholesterolemia). During a preliminary observation period, the serum cholesterol level was determined at least two times at intervals of 2-4 weeks, and the criterion for a diagnosis of hyperlipidemia was a serum cholesterol value of at least 220 mg/dl at each determination. The age range for eligibility was 18-65 years in principle, while there were no restrictions with regard to gender. Before the start of this study, details of the trial were explained to each of the subjects, and informed consent was obtained from each patient. Exclusion criteria were liver disease, serious renal disease (including nephrosis), recent myocardial infarction or apoplexy, heart failure, and secondary hyperlipidemia. Patients were also excluded if they were hypersensitive to drugs, might be pregnant, were pregnant, or were breast feeding.
Experimental Methods
Experimental drugs. The experimental drugs employed in this clinical study were simvastatin, 2.5-and 5-mg tablets, and the corresponding placebo tablets. The indistinguishability of the actual drugs and placebos was confirmed by the controller (see "Appendix"). To preserve the double-blind nature of this study, the double-dummy method was applied. The combination of active drug and placebo tablets shown in Figure 1 was placed in envelopes for allocation to the subjects.
Administration method and schedule ( Figure 2 ). Antihyperlipidemic drugs that were being administered before this study were discontinued, and each patient received placebo tablets twice each day (after the morning and evening meals) for 4 weeks. However, in the case of a patient who had been receiving a drug (e.g., probucol) that exerted a long-term effect on the serum lipid profile, a long observation period was instituted, and it was then confirmed, on the basis of serum lipid values, that the effects of the drug had been eliminated before inclusion of the patient in this study.
During the treatment period, the assigned experimental drugs shown in Figure 1 were administered two times each day for 12 weeks, and after completion of the treatment period, placebo tablets were again administered to the patients for 4 weeks as a follow-up observation period.
During the experimental period, the subjects were instructed not to change their eating habits from those before the study, and alcohol consumption was prohibited on the day before tests were performed. In addition, concomitant administration of drugs known to affect serum lipid levels was prohibited.
Determination of serum lipid parameters. Fasting blood samples were collected from each subject before the start of drug administration (weeks -4 and 0), during the treatment period (weeks 4, 8, and 12) , and during the follow-up observation period (week +4). The serum was separated from the blood and stored in a freezer until assay at a central (39) 8 (5) 22 (15) 102 (68) 26 (17) Values are numbers in each group and (percent). FH, familial hypercholesterolemia.
laboratory (SRL Co., Tokyo, Japan) for the serum lipid parameters described below.
To determine the serum lipid profile, concentrations of the following parameters were determined: total cholesterol (TC), high density lipoprotein (HDL) cholesterol, triglycerides (TGs), LDL cholesterol, and apolipoproteins (apos A-I, A-II, B, C-II, C-III, and E). The TC and TG concentrations were determined by enzymatic methods, 1516 while the HDL cholesterol concentration was determined by the heparin-calcium precipitation method. 17 The LDL cholesterol concentration was calculated according to the Friedewald equation. 18 LDL cholesterol=TC-HDL cholesterol-(TG/5)
The concentrations of the apolipoproteins were determined by the single radial immunodiffusion method. 19 Safety studies. With the objective of evaluating the safety of administration of the experimental drug, the following tests and determinations were performed before the start of drug administration (week 0), during the treatment period (weeks 4, 8, and 12), and on completion of the follow-up observation period (week +4): physical examination (including determination of body weight, blood pressure, and pulse rate); general hematologic tests; urinalysis; serum biochemistry tests (total protein, total bilirubin, glutamic oxaloacetic transaminase, glutamate-pyruvate transaminase, y-glutamyl transpeptidase, lactate dehydrogenase, alkaline phosphatase, creatine phosphokinase, uric acid, blood urea nitrogen, creatinine, albumin to globulin ratio, fasting blood sugar, Na + , K + , Cl~, and Ca 2+ ); and antinuclear antibody. Statistical analysis. For statistical analysis of the data, the x 2 t e s t w a s applied to the patients' background data, while Wilcoxon's one-sample test was employed to compare preadministration and postadministration values for the various serum lipid parameters. The Mann-Whitney U test was employed for group comparisons of the values for the various serum lipid parameters. In this study, the value for the mean percent decrease in TC level from the fourth through the 12th weeks of administration was also used for statistical analysis. The x 2 t e s t w a s u s e d for group comparisons of the incidence of adverse reactions and the incidence of abnormal laboratory test values.
Results

Patients' Characteristics
The patients' characteristics are summarized in Table 1. No statistically significant differences were found among the various patient groups in relation to the patients' background factors. All patients were outpatients, and the proportion of patients with a primary diagnosis of familial hypercholesterolemia was 15%.
Effect of Simvastatin on Serum Lipids
Total cholesterol level. Tables 2 and 3 summarize the data for the changes in serum TC level. In each of the patient groups administered simvastatin (i.e., the 2.5-mg q.a.m., the 2.5-mg q.p.m., the 5-mg q.a.m., and the 5-mg q.p.m. groups), the TC level was significantly lowered from the fourth through the 12th weeks of drug administration. The values for the mean percent decrease in TC level from the fourth through the 12th weeks in each simvastatin administration group were 10.9%, 15.4%, 13.7%, and 20.7%, respectively. The greatest percent decrease was thus achieved in the 5-mg q.p.m. simvastatin group. In contrast, in the placebo group no decrease in TC level was detected throughout the treatment period. It was found that for both the 2.5-mg and the 5-mg dosages of simvastatin, the percent decrease was significantly (/J<0.05) greater in the evening group 127.3±51.6 (-0.1) [22] 152.2±68.9 (10.8) [18] 164.3 ±103.6 (10.9) [22] Values are mean±SD in mg/dl, by the Wilcoxon test. Also shown are (percent change) and [number of subjects].
*p< 0.001. than in the morning group. In addition, when the two evening dosages of simvastatin were compared, it was found that the 5-mg dosage produced a significantly (/?<0.05) greater reduction in TC level than did the 2.5-mg dosage. Moreover, it was found that for each of the simvastatin administration groups, TC levels returned to approximately baseline (pretreatment) values by the end of the 4-week follow-up period (week +4) after completion of the drug administration schedule.
Triglycerides. As shown in Table 4 , no statistically significant changes from baseline levels (week 0) were found in the simvastatin administration groups and the placebo group at 12 weeks in relation to the serum TG levels.
High density lipoprotein cholesterol. As shown in Table 5 , no significant changes in serum HDL cholesterol level were detected in the placebo group. However, with the exception of the simvastatin 5-mg q.a.m. group, HDL cholesterol levels were significantly increased from baseline levels (week 0) in each of the simvastatin administration groups. The changes in HDL cholesterol level in each group were not significantly different from the changes found in the placebo group.
Low density lipoprotein cholesterol. The pattern of change in serum LDL cholesterol levels is shown in Tables 6 and 7 . In each of the simvastatin administration groups, LDL cholesterol level was significantly decreased after the fourth week of drug administration. No decrease was detected in the Comparison of results between morning and evening regimens shows that for both the 2.5-and the 5-mg dosages of simvastatin, the percent decrease in LDL cholesterol value was larger with the evening regimen than with morning administration. With the 5-mg dosage, the percent decrease achieved with the evening regimen was significantly superior to that achieved with the morning regimen (/?<0.05).
On comparison of the effects of the two simvastatin dosages, it is clear that the percent decreases in the 5-mg groups were larger than those in the 2.5-mg groups, but the differences between these values were not statistically significant.
Changes in apolipoprotein levels.
APOLIPOPROTEIN A-I. AS shown in Table 8 , the serum level of apo A-I was found to not have under- gone any change in any of the simvastatin administration groups during the experimental period.
APOLIPOPROTEIN A-II. The serum level of apo A-II was found to not have undergone any change in any of the simvastatin administration group at 12 weeks (Table 9) . APOLIPOPROTEIN B. AS shown in Tables 10 and 11 , the serum level of apo B was found to be significantly reduced in each of the simvastatin administration groups beginning from the fourth week of the treatment period.
Pairwise comparison of the results between the morning and evening regimens shows that the percent decrease in the apo B level was larger with the evening regimen than with morning drug administration, but the difference was not statistically significant. At the fourth and eighth weeks of drug administration, the percent decrease achieved with the 5-mg evening regimen was significantly superior to that achieved with the 5-mg morning regimen O<0.05).
APOLIPOPROTEIN C-II. AS shown in Table 12 , the serum level of apo C-II was found to be significantly reduced in each of the simvastatin administration groups beginning from the fourth week of the treatment period. The simvastatin administration groups did not show any significant differences from the placebo group. APOLIPOPROTEIN C-III. The serum level of apo C-III was found to be significantly reduced from the baseline value in each of the simvastatin groups (e.g., 2.5-mg q.a.m., 2.5-mg q.p.m., and 5-mg q.p.m.) at the 12th week, except for the 5-mg q.a.m. group (Table 13) .
APOLIPOPROTEIN E. AS shown in Table 14 , the serum level of apo E was found to be significantly reduced in each of the simvastatin administration groups beginning with the fourth week of the treatment period. The efficacy of simvastatin in lowering serum apo E levels was not found to differ significantly as a function of time (morning versus evening) of administration or as a function of dosage (2.5 versus 5 mg).
Safety
Adverse reactions. Various symptoms were recorded on the case cards by the investigators, and those for which a cause-effect relation with the administered drug could not be ruled out were handled as adverse reactions. Adverse experiences are shown in Table 15 .
The numbers of cases of adverse reactions and the incidence of adverse reactions in each of the drug administration groups were as follows: two cases (5.7%) in the 2.5-mg q.a.m. group, one case (2.9%) in the 2.5-mg q.p.m., two cases (6.3%) in the 5-mg q.p.m. group, and one case (2.9%) in the placebo group. There were no adverse reactions in the 5-mg q.a.m. group. Thus, there was no difference between the simvastatin administration groups and the placebo group in terms of the incidence of adverse reactions. Drug administration had to be discontinued in two patients (5.7%) in the 2.5-mg q.a.m. group, in one patient (2.9%) in the 2.5-mg q.p.m. group, and in one patient (3.1%) in the 5-mg q.p.m. group. The two patients in the 2.5-mg q.a.m. group were a 60-year-old woman who experienced pyrosis and eructations and a 61-year-old man who experienced impotence, decreased libido, and abnormali- ties of the mucous membranes (swelling, taste blindness, and hoarseness). The 2.5-mg q.p.m. group patient was a 54-year-old woman who experienced diarrhea, and the 5-mg q.p.m. group patient was a 39-year-old woman who experienced edema of the legs.
These adverse reactions did not require any special treatment, and they all disappeared after drug administration was discontinued.
Laboratory test abnormalities. No seriously abnormal laboratory findings were reported, and no patient was withdrawn from the study due to such an occurrence. One patient in the 2.5-mg q.a.m. group had serum glutamic oxaloacetic transaminase and glutamate-pyruvate transaminase values more than three times the upper limit of normal on at least one occasion, and one patient each in the 2.5-mg q.p.m., the 5-mg q.a.m., and the 5-mg q.p.m. group had abnormal values above the upper limit (less TABLE 16 . Changes in Laboratory Test Values than twice normal) for serum glutamic oxaloacetic transaminase and/or glutamate-pyruvate transaminase. In four patients, one patient in the 2.5-mg q.a.m., two patients in the 2.5-mg q.p.m., and one patient in the placebo group, serum creatine phosphokinase levels increased from normal to abnormal values, but the increases were within two times the upper limit.
The changes in mean values of serum glutamic oxaloacetic transaminase, glutamate-pyruvate transaminase, and creatine phosphokinase are shown in Table 16 . The changes in all these groups were not large, and none of them was considered to represent a clinical problem.
Ophthalmological examinations (slit-lamp and funduscopy) were performed if required, but none of the patients in the simvastatin administration groups showed any change from normal to abnormal findings or showed aggravation of an existing abnormality. 
Discussion
The present clinical study was performed to determine the most effective time of administration of simvastatin to maximize its efficacy as a single daily dose with doses of 2.5 and 5 mg.
Comparison of the percent reductions in TC produced by the morning and evening regimens of simvastatin revealed that, in general, for both the 2.5-and the 5-mg dose, evening administration resulted in significantly greater reductions than did morning administration (/?<0.05).
Similar results have also been obtained with lovastatin when the efficacy of a morning and an evening dose was compared. Although the percent decreases in serum TC and LDL cholesterol with 40 mg q.a.m. lovastatin were 21% and 27%, respectively, the percent decreases with 40 mg q.p.m. were 27% and 32%, respectively. 20 Therefore, administration of a single daily dose of this drug in the evening results in maximum expression of its inhibitory activity at the time when cholesterol biosynthesis is most active, and this finding can be related to the efficacious reduction of the serum TC level.
The 5-mg dosage resulted in larger reductions than did the 2.5-mg dosage, regardless of whether the time of administration was morning or evening. The percent decreases in serum TC and LDL cholesterol with the 2.5-mg q.p.m. dose were 15.4% and 22.2%, respectively, and were 20.7% and 28.5%, respectively, with the 5-mg q.p.m. dose.
On the other hand, the results of studies conducted in the United States and Europe have revealed that the percent decreases in serum TC and LDL cholesterol produced by simvastatin were 21% and 24-28%, respectively, with 10 mg; 26-27% and 32-34%, respectively, with 20 mg; and 33% and 40% with 40 mg q.p.m., respectively.
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When the results of this study conducted in Japan were compared with those in the United States and Europe, similar cholesterol-lowering effects were obtained with smaller doses of simvastatin in this study.
This difference may be attributed to a disparate response based on race and physical differences of the patients who entered the studies in Japan and in the countries in Europe and the United States.
Serum TG levels were found to not have undergone any change as a result of simvastatin administration. However, administration of simvastatin has resulted in reductions of TG levels in patients with elevated serum TG values in a phase 2 open clinical study. 12 In our present study, more than half the patients in each drug administration group had a serum TG value that was within the normal range at baseline. Therefore, it is difficult to assess the effects of simvastatin on serum TG levels in this study.
The serum HDL cholesterol level showed a tendency to increase in response to administration of simvastatin. This action mechanism is not currently understood, but it has been reported that the HDL cholesterol level was elevated after administration of another HMG:CoA reductase inhibitor. 22 Therefore, we surmise that this action is an integral aspect of the overall action mechanism of simvastatin.
The serum LDL cholesterol value, calculated by use of the Friedewald equation, was found to be significantly lowered by administration of simvastatin, and the magnitude of the decrease was greater with the evening administration regimen than with the morning administration regimen. Furthermore, the decreases in LDL cholesterol level and in TC level occurred in parallel, and the absolute amounts of those decreases were comparable. Therefore, the decreases in TC level can be regarded as an indicator of a decrease in the LDL cholesterol level, and it is also assumed that this effect is an improvement that may result in the antiatherosclerotic action of simvastatin.
Although HDL cholesterol levels showed a tendency to increase in response to administration of simvastatin, the values of the principal HDL apolipoproteins, A-I and A-II, did not change in this study. However, significant increases were attained in HDL cholesterol (8%), apo A-I (5%), and apo A-II (4%) with simvastatin in another study, 23 so these data indicate that simvastatin increased apo A-I and apo A-II slightly, as well as increasing HDL cholesterol values.
On the other hand, apo B, the principal LDL apolipoprotein, was significantly decreased by administration of simvastatin, and the pattern of change in its concentration was similar to the pattern of change in the serum LDL cholesterol level. The percent decrease in the level of apo B was greater in the evening administration group.
Although reductions in apo C-II and apo C-III in the simvastatin administration groups were larger than in the placebo group, the differences were not significant. However, since the levels of apo C-II and apo C-III were reduced by simvastatin in other studies, 23 -24 these reductions may be related to the efficacy of simvastatin.
The level of apo E decreased in response to administration of simvastatin. This decrease may be closely related to the mechanism of action of simvastatin, which inhibits the biosynthesis of cholesterol and accelerates LDL receptor activity in the liver. As apo E is contained mainly in very low density lipoprotein, the decrease in apo E may be based on the decrease of very low density lipoprotein cholesterol, which occurred with simvastatin administration. 25 The evaluation and analysis of the safety profile of simvastatin showed adverse reaction rates of 5.7% in the 2.5-mg q.a.m. group, 2.9% in the 2.5-mg q.p.m. group, 0% in the 5-mg q.a.m. group, and 6.3% in the 5-mg q.p.m. group. These were not statistically significant different from the 2.9% incidence recorded for the placebo group. The incidences of adverse reactions with simvastatin in this study were not higher than those of other studies (3.6-12%) 910 or of lovastatin studies (10-14%) . 2627 Most of the adverse reactions consisted of digestive system symptoms, which have been reported in other studies, and the symptoms disappeared after discontinuation of the drug, even in those patients who had to be taken off the treatment regimen. There were no adverse reactions that were considered to represent a clinical problem of particular importance, so it can be concluded that simvastatin is a generally well-tolerated drug.
Laboratory test abnormalities such as elevations in glutamic oxaloacetic transaminase and glutamatepyruvate transaminase detected in the simvastatin administration groups were transient, and the same phenomena have been reported for other drugs used in the treatment of hyperlipidemia.
2022 None of these abnormalities was considered to represent a problem of particular clinical importance.
In consideration of the findings discussed above, simvastatin provides excellent efficacy in improving the serum lipid profile, and its efficacy is greater when the drug is administered in the evening rather than in the morning. Moreover, simvastatin is a generally well-tolerated drug whether it is administered in the morning or the evening. Accordingly, if simvastatin is to be administered in a single daily dose, the most effective administration time is during the evening.
In addition, in this clinical study employing doses of 2.5 mg and 5 mg, the efficacy of simvastatin was found to be dose dependent. It can be concluded that within the scope of this clinical study, the recommended administration regimen should be a 5-mg evening dose of simvastatin.
